natgillin/translations-raw huggingface dataset:
A composition comprising a combination of (i) at least one inhibitor of platelet aggregation selected from clopidogrel, cilostazol, ticlopidine, and tirofiban and (ii) a compound selected from mecamylamine, irbesartan, idraparinux, otamixaban, and SR48692, or salts or prodrugs or derivatives or sustained release formulations thereof, for use in the treatment of neuroinflammation. 
Sastav sadrži (i) najmanje jednu tvar odabranu između klopidogrela, cilostazola, tikolopidina, ili tirofibana, u kombinaciji s (ii) jednom tvari odabranom između mekamilamina, irbesartana, idraparinuksa ili otamiksabana, ili njihovih soli ili formulacija za postepeno oslobađanje za uporabu u liječenju neuroinflamacije.
A conjugate comprising an antibody of any one of items 1-19 coupled to a therapeutic agent. The conjugate of item 20, wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent. 
Konjugat koji se sastoji od antitijela suglasno bilo kojem zahtjevu 1-11, povezanog sa nekim terapeutskim agensom, poželjno toksinom ili radioizotopom, lijekom ili nekim citotoksičnim agensom.
An antibody active agent conjugate, wherein the antibody has an amino acid motif that can be recognized by an isoprenoid transferase, wherein the active agent is covalently linked to the antibody at the amino acid motif, wherein the amino acid motif is CAAX, XXCC, XCXC, or CXX, wherein C represents cysteine, A represents an aliphatic amino acid, and X represents an amino acid that determines a substrate specificity of the isoprenoid transferase; and wherein the amino acid motif is covalently linked to the active agent via at least one linker, wherein the at least one linker is an isoprenyl derivative that can be recognized by the isoprenoid transferase, whereby the linker is represented by the formula (I): wherein 
Konjugat aktivnog sredstva protutijela, naznačen time, da antitijelo ima motiv aminokiseline koji se može prepoznati izoprenoid transferazom, pri čemu je aktivno sredstvo kovalentno vezano za antitijelo na motivu aminokiseline, pri čemu je aminokiselinski motiv CAAX, XXCC XCXC, ili CXX, pri čemu C predstavlja cistein, A predstavlja alifatsku aminokiselinu, a X predstavlja amino kiselinu koja određuje supstratnu specifičnost izoprenoid transferaze;
In another preferred embodiment of the pharmaceutical methods of the invention, the pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct is to be administered by continuous infusion for at least four weeks followed by a 2-week treatment-free interval. 
Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što farmaceutski pripravak koji sadrži CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primjenjivati kontinuiranom infuzijom najmanje četiri tjedna, za čim slijedi dvotjedni interval bez liječenja.
The siliconized container means of claim 1, wherein the pH buffered saline solution in the formulation has a pH of 5.5 to 7.5. 
Formulacija u skladu s patentnim zahtjevom 1, naznačena time što navedena fiziološka otopina s puferiranim pH ima pH od 5,5 do 7,5.
The composition according to claim 1, wherein the plasticiser is selected from the group consisting of acetyl tributyl citrate, glycerol triacetate, acetyl triethyl citrate, acetyl ethyl citrate, diethyl sebacate, dibutyl sebacate, ethyl and dibutyl phthalate, polyethylene glycol, glycerol and propylene glycol. 
Pripravak u skladu patentnim zahtjevom 4, naznačen time, da se plastifikator bira između acetil tributil citrata, glicerol triacetata, acetil trietil citrata, acetil etil citrata, dietil sebacata, dibutil sebacata, etil i dibutil ftalata, polietilen glikola, glicerola i / ili propilen glikola.
The method of claim 7, wherein the testing device includes one or more test scripts, including test commands defined therein which, when executed by the media device under test, cause the media device under test to issue requests for the playback or other control of media content associated with the test files. 
Postupak prema zahtjevu 6 ili 7, naznačen time da sustav sadrži jednu ili više testnih skripti (340), uključujući definirane testne naredbe koje, kada se izvršavaju putem medijskog uređaja (350) prilikom testiranja, uzrokuju da medijski uređaj izdaje zahtjeve za pristup mediju za nadziranje, npr. za reprodukciju, medijskog sadržaja povezanog s testnim datotekama (332, 334, 336).
Compounds according to claim 1 which conform to Formula (II): and pharmaceutically acceptable salts, solvates, solvates of salts, thereof in which R1, R2, R3, R4 and R5 have the meaning indicated for Formula (I). 
Spojevi prema zahtjevu 1 naznačeni time da odgovaraju Formuli (II): L f-p2 (DD i njihove farmaceutski prihvatljive soli, solvati ili solvati soli gdje R', R", R*, R* i R? imaju značenje navedeno za Formulu (I).
The engineered polypeptide of any of the preceding Clauses, wherein the improved property is selected from reduced sensitivity to proteolysis and/or increased tolerance to acidic pH. 
(iv) da je poboljšana osobina odabrana od reducirane osjetljivosti na proteolizu 1/ili povećane tolerancije na kiselu pH.
Management of DMR Signalling Features, Including Voice Call Set-Up, and DMR Data Features Using the SIP MESSAGE Method 
- upravlja DMR signalizacijskim obilježjima, uključujući uspostavljanje glasovnog poziva, i DMR obilježja podataka uporabom SIP MESSAGE/SIP PORUKA metode; i
In other embodiments, said amino (ammonium) has a general formula (V): wherein each of R′, R″ and R′″ is independently selected from a group consisting of straight or branched C1-C9 alkyl, straight or branched C1-C9 alkenyl, straight or branched C1-C9 alkynyl. 
PATENTNI ZAHTJEVI nos Spoj opće formule (IV): pri čemu je svaki RI-R8 neovisno odabran iz skupine koja sadrži H, OH, SH, halogen, nitro, amino, nitrilo, nitrozo, acetil, acetamid, aciklamid, alkilamin, ravan ili razgranati C1- C5 alkil, ravan ili razgranati C1-C5
“Heteroaryl” means a monocyclic or a bicyclic aromatic hydrocarbon ring having from 2 to 10 carbon atoms and from 1 to 4 heteroatoms, such as O, S or N. The heteroaryl ring may optionally be fused to another heteroaryl, aryl or aliphatic cyclic group. 
"heteroaril" znači monociklički ili biciklički aromatski ugljikovodički prsten s 2 do 10 atoma ugljika i od 1 do 4 heteroatoma, poput O, S ili N, te koji može izborno biti kondenziran s drugim heteroarilom, arilom ili alifatskom prstenastom skupinom, te koji može biti supstituiran s istim supstituentima kao što je specificirano za aril, gore;
an optional water-soluble separating layer; and an enteric coating, characterized in that the enteric coating layer has a thickness of 85 µm to 150 µm and in that the pantoprazole is present in the form of particles having an average particle size within the range of 60 µm to 250 µm, which particles consist of pantoprazole and are obtainable by a process comprising the steps of wetting pantoprazole with water in a high shear mixer, passing the wet pantoprazole through a sieve having a mesh size within the range of 0.8 to 2 mm, and drying the mass in a fluid bed dryer, the order of the sieving and drying step being optional. 
enterička obloga, naznačen time, da sloj enteričke obloge ima debljinu od 85 um do 150 um, te time, da je pantoprazol prisutan u obliku čestica koje imaju prosječnu veličinu čestice unutar raspona od 60 um do 250 um, pri čemu se te čestice sastoje od pantoprazola i mogu se dobiti putem postupka koji obuhvaća korake vlaženja pantoprazola s vodom u brzoreznoj mješalici, prolaženja vlažnog pantoprazola kroz sito koje ima veličinu otvora mreže unutar raspona od 0,8 do 2 mm, te sušenja smjese u sušilici s fluidiziranim slojem, pri čemu se poredak za korake prosijavanja i sušenja, namješta prema potrebi.
calculation of a roll angle on the basis of the first, second and third signals, estimated projectile control force, measured projectile velocity and measured rotational velocity, by summation of an absolute angle change, where the absolute angle change is set to correspond to the resultant angle of the change in pitch angle of the projectile velocity vector and the change in yaw angle of the projectile velocity vector, with weighting of an angle evaluation, where the angle evaluation is determined as a mean value of the angle of incidence evaluation, where the mean value of the angle of incidence evaluation is set to correspond to the mean value of the resultant angle of the projectile control force which controls the yaw component, B, of the angle of incidence and the projectile control force which controls the pitch component, a, of the angle of incidence. 
izračunavanje kuta valjanja na temelju prvog, drugog i trećeg signala, procijenjene kontrolne sile projektila, izmjerene brzine projektila i izmjerene rotacijske brzine, zbrajanje apsolutne promjene kuta, gdje je apsolutna promjena kuta postavljena da odgovara rezultirajućem kutu od promjene vektora brzine za kut propinjanja projektila i promjene vektora brzine za kut skretanja projektila, s ponderiranjem procjene kuta, gdje se procjena kuta određuje kao srednja vrijednost procjene upadnog kuta, gdje je procjena srednje vrijednosti upadnog kuta postavljena da odgovara srednjoj vrijednosti rezultirajućeg kuta kontrolne sile projektila koja kontrolira komponentu skretanja, B, upadnog kuta i kontrolnu silu projektila koja kontrolira komponentu propinjanja, a, upadnog kuta.
An in vitro method of inhibiting immune cell activation comprising administering to the cell a compound of formula (I): or a pharmaceutically acceptable salt, solvate, or clathrate thereof wherein: 
PATENTNI ZAHTJEVI L In vitro postupak inhibicije aktivacije imunoloških stanica naznačen time da se sastoji od primjene na stanicu spoja formule (I):
A capsule according to claim 16, wherein the capsule is hermetically closed. 
Kapsula prema patentnom zahtjevu 14, pri čemu je kapsula (110) hermetički zatvorena.
A process according to claim 1 wherein the hydrocarbon is selected from the group consisting of natural gas, refinery off-gas, associated gas, natural gas condensates, ethane, propane, butane, liquefied petroleum gas, light naphtha, heavy naphtha, kerosene, gas oil, coke oven gas, and town (coal) gas. 
2. Postupak prema zahtjevu 1 gdje je ugljikovodik prirodan plin, ispušni plin rafinerije, vezani plin, kondenzati prirodnog plina, etan, propan, butan, ukapljeni naftni plin, laka nafta, teška nafta, kerozin, plinsko ulje, plin iz koksne peći i gradski (ugljen) plin.
Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor. 
Uporaba polinukleotida koji kodira polipeptid koji sadrži vanstanične IPT-3 i IPT-4 domene receptora faktora rasta hepatocita za pretraživanje farmakološki aktivnih tvari korisnih za liječenje raka.
The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is Cl, Br, methyl or trifluoromethyl. 
Spoj u skladu s patentnim zahtjevom 1, ili njegova farmaceutski prihvatljiva sol, naznačen time što R3 je Cl, Br, metil ili trifluormetil.
contacting a compound which stimulates functionality of the receptor in step (b) in vitro with a mammalian enteroendocrine cell; and 
(c) stavljanja u kontakt spoja koji stimulira funkcionalnost receptora u koraku (b) in vitro s enteroendokrinom stanicom sisavca; te
From these results and the structural similarity of these compounds to TLK199, the compounds, especially as the diesters, are expected to act therapeutically to: potentiate the cytotoxic effects of chemotherapeutic agents in tumor cells, selectively exert cytotoxicity in tumor cells, elevate the production of GM progenitors in bone marrow, stimulate the differentiation of bone marrow, mitigate the myelosuppressive effects of chemotherapeutic agents, and modulate hematopoiesis in bone marrow. 
Iz rezultata i strukturne sličnosti ovih spojeva TLK 199, spojevi, posebno kao diesteri, očekivano djeluju terapeutski na: pojačavanje citotoksičnih efekata kemoterapijskih agenasa u stanicama tumora, selektivno očitovanje citotoksicitete u stanicama tumora, podizanje produkcije GM progenitora u koštanoj srži, stimuliranje diferencijacije u koštanoj srži, ublažavanje mielosupresivnih efekata kemoterapijskih agensa, i moduliranje hematopoiesisa u koštanoj srži. Primjer Formulacije.
Viewed from another aspect the invention provides an organophosphate or carbamate for use in a method of treatment of farmed fish to combat infestation by multicellular ectoparasites with exoskeletons which method comprises topically exposing farmed fish, especially fish in cages, to a first and a second sea lice treatment agent sequentially, said first sea lice treatment agent being a carbamate or organophosphate and said second sea lice treatment agent being a pyrethroid or pyrethrin, wherein exposure to the first sea lice treatment agent is effected 10 minutes to 12 hours before exposure to the second sea lice treatment agent. 
Piretroid ili piretrin za uporabu u postupku tretmana uzgajanih riba radi borbe protiv infestacije višestaničnim ektoparazitima sa egzoskeletom, taj postupak obuhvaća uzastopni topikalni tretman uzgajanih riba s prvim i drugim sredstvom protiv morskih uši, to prvo sredstvo protiv morskih uši je karbamat ili organofosfat i drugo sredstvo protiv morskih uši je piretroid ili piretrin, pri čemu izloženost prvom sredstvu protiv morskih uši traje 10 minuta do 12 sati prije izlaganja drugom sredstvu protiv morskih uši.
applying a coating solution or dispersion comprising sulfonated polyether ether ketone (sPEEK) and cellulose acetate (CA) to a first surface of a microporous substrate and allowing the coating solution or dispersion to dry to form an air impermeable selective layer as a substantially non porous film on the first surface of the substrate, wherein the coating solution or dispersion comprises an sPEEK:CA (wt.:wt.) ratio in the range of 7:3 to 2:3, the acetyl content of the CA is 20% to 62%, the degree of sulfonation of the sPEEK is in the range of 23% to 100%; and 
nanošenje otopine ili disperzije premaza koji sadrži sulfonirani poli-eter-eter-keton (sPEEK) i celulozni acetat (CA) na prvu površinu mikroporoznog supstrata i omogućavanje da se otopina ili disperzija premaza osuše da se formira zračno nepropusni selektivni sloj kao bitno neporozan film na prvoj površini supstrata, pri čemu otopina ili disperzija premaza sadrži maseni omjer sPEEK:CA u rasponu od 7:3 do 2:3,sadržaj acetila CA je 20% do 62%, stupanj sulfoniranosti sPEEK-a je u rasponu od 23% do 100%; i naznačeno time što selektivni sloj ima debljinu manju od 5 mikrona.
In particular said binding partner comprises the amino acid sequences of SEQ ID NO:3 and NO:4. 
Fragment protutijela u skladu s patentnim zahtjevom 2, pri čemu fragment sadrži aminokiselinske sljedove iz SEQ ID NO:3 i SEQ ID NO:4.
The set of floor panels as claimed in claim 1, wherein a displacement of the displaceable tongue in a second direction along the first and second edges causes the displacement of the tongue in the first direction such that the displaceable tongue enters into the tongue groove. 
Komplet podnih ploča prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da glavno tijelo jezika sadrži spoj klinastog dijela (46) koji se nalazi u udubljenju (43).
The pharmaceutical composition of claim 7, wherein the meta-cresol concentration is about 3.15 mg/mL. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 10, naznačen time što je koncentracija meta-krezola otprilike 3,15 mg/ml.
An overview of the experiment is shown below: 
Broj objave europskog patenta:
A compound or salt according to Claim 9 for use in the treatment of congestive heart failure, hypertension, diabetic nephropathy, or chronic kidney disease. 
Spoj ili sol u skladu s patentnim zahtjevom 4, naznačen time što je namijenjen upotrebi u liječenju kongestivne srčane insuficijencije, hipertenzije, dijabetične nefropatije ili kronične bolesti bubrega.
However it can happen that ground scrap from ABS and/or extruded PMMA slabs is accidentally contaminated with crosslinked PMMA, making recycling problematical. 
Međutim, može se dogoditi da je mljeveni otpad od ABS i/ili ekstrudiranih PMMA ploča nenamjerno kontaminiran s umreženim PMMA, što čini recikliranje problematičnim.
A compound according to claim 1, wherein the compound is 4,5-dihydroxy-2-(1-methyl-1H-pyrrol-2-yl)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4,5-dihidroksi-2- (1-metil-1H- pirol-2-il) izoftalo nitril.
f is an integer from 0 to 4, such that when (f x s) is greater than 1, the Y' groups are the same or different; 
f je cijeli broj od 0 do 4, tako da kada je (f x s) veće od 1, Y’ skupine su iste ili različite;
Use of a cyclosporin according to claim 1 in the preparation of a pharmaceutical composition for inhibiting HCV replication. 
Uporaba ciklosporina u skladu sa zahtjevom 1, naznačena time, da se koristi za pripravu farmaceutskog pripravka za inhibiciju HCV replikacije.
Use of a magnetostrictive radiator as an electro-acoustic transducer as a result of a higher Curie point as compared to the use of piezoceramics allows one to substantially increase the operating temperatures for crying out the method. 
Uporaba magnetostriktivnog radijatora kao elektroakustičnog prijenosnika što je rezultat više Curie točke u odnosu na uporabu piezokeramike, a to omogućuje značajno povećanje radne temperature za provođenje postupka.
Water (100 ml) was added and the mixture extracted with ethyl acetate (3 x 250 ml). 
Doda se voda (100 ml) i smjesa se ekstrahira etil acetatom (3 x 250 ml).
represents alkylaryl, carboxy, alkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyl, cycloalkyl, cycloalkenyl, carbamoyl, hydroxyalkyl, aryloxy, alkoxycarbonyloxy, alkoxycarbonyl, alkoxy, alkoxyalkyl, aryl, a heterocyclic ring, aminocarbonyl, alkylthio, alkylcarbonylamino, arylcarbonyl, hydroxy, alkylcarbonyl, alkylcarbonyloxy, or amino, all of which are optionally substituted by one or more, same or different substituents selected from R8; 
predstavlja alkilaril, karboksi, alkil, alkenil, cikloalkenil, alkinil, haloalkil, cikloalkil, cikloalkenil, karbamoil, hidroksialkil, ariloksi, alkoksikarboniloksi, alkoksikarbonil, alkoksi, alkoksialkil, aril, heterociklični prsten, aminokarbonil, alkiltio, alkilkarbonilamino, arilkarbonil, hidroksi, alkilkarbonil, alkilkarboniloksi ili amino, gdje su svi oni izborno supsitituirani sa jednim ili više, istih ili različitih supstituenata izabranih od R8;
The mixture was kept under stirring for 6 hours, the solvent was evaporated off and the residue was freeze-dried, thereby obtaining the final compound as a white solid. 
Smjesa je miješana 6 sati, otapalo je upareno a ostatak je liofiliziran i time je dobiven konačni spoj kao bijela krutina.
Use of a compound of formula (I): for the preparation of the dihydrochloride salt of formula (II): 
(I), poželjno u suspenziji, te na taj način nastaje navedena dihidrokloridna sol s formulom (II): O
A compound according to any one of claims 1-13 for use in therapy. 
Spoj za uporabu sukladno zahtjevu 7 pri čemu je kožni poremećaj psorijaza.
The combination according to claim 2 wherein the auto-immune disease is rheumatoid arthritis, glomerulonephritis, multiple sclerosis, Crohn's disease, ulcerative colitis, systemic lupus erythematosus or psoriasis. 
Kombinacija sukladno patentnom zahtjevu 2, naznačena time, da je autoimuna bolest reumatoidni artritis, glomeruloneftitis, multipla skleroza, Crohnova bolest, ulcerozni kolitis, sistemski lupus eritematosus ili psorijaza.
Use according to any one of the embodiments 23 to 25, wherein the freeze-dried molded article is moistened with water or an aqueous solution of one or more active substances and/or, optionally, auxiliary substances and decomposes and is then applied onto the skin or hair. 
Uporaba sukladno zahtjevu 10, pri čemu je liofilizirani oblikovani proizvod navlažen vodom ili vodenom otopinom jedne ili više aktivnih supstanci i/ili, ukoliko je primjenjivo, pomoćnih supstanci, te se otapa i posljedično se primjenjuje na kožu ili kosu.
A method of treating a disorder or disease selected from the group consisting of inflammatory bowel disease, rheumatoid arthritis, psoriasis, glomerulonephritis, and systemic lupus erythematosus in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula Ib, or a pharmaceutically acceptable salt thereof: 
Spoj kako je definirano u zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za uporabu za liječenje poremećaja ili bolesti, pri čemu je poremećaj ili bolest odabrana od: polipoze kolona, retinalne angiogeneze, odonto-oniho-dermalne displazije, Wilmsovog tumora, koštane displazije, te fokalne dermalne hipoplazije.
a ceramic spool having a first end and a second end, a flexural strength of at least 15 MPa and an external diameter D and at least the first end of the ceramic spool has an axial, centered bore of a diameter d, and a depth Dd≤1.5 d and, 
keramički kalem (2), čija je čvrstoća na savijanje najmanje 15 MPa i vanjski promjer D, a najmanje jedan kraj keramičkog kalema ima aksijalni centrirani provrt promjera d i dubine Dd ≥1,5 d i,
A combination comprising a therapeutically effect amount of a compound of any one of claims 1-20 and one or more additional therapeutically agents and optionally further comprising a pharmaceutically acceptable carrier, wherein the additional therapeutically agent is independently selected from antibiotics, antibacterial agents, antiemetic agents, antifungal agents, anti-inflammatory agents, antiviral agents, immunomodulatory agents, cytokines, antidepressants, hormones, alkylating agents, antimetabolites, antitumour antibiotics, antimitotic agents, topoisomerase inhibitors, cytostatic agents, anti-invasion agents, antiangiogenic agents, inhibitors of growth factor function, inhibitors of viral replication, viral enzyme inhibitors, anticancer agents, a-interferons, B-interferons, ribavirin, and toll-like receptor modulators. 
Kombinacija, naznačena time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 20, ijedno ili više dodatnih terapeutskih sredstava, te po želji nadalje obuhvaća farmaceutski prihvatljiv nosač, pri čemu je dodatno terapeutsko sredstvo neovisno odabrano od sljedećih: antibiotici, antibakterijska sredstva, antiemetici, antifungalna sredstva, protuupalna sredstva, antivirusna sredstva, imunomodulatori, citokini, antidepresivi, hormoni, alkilacijska sredstva, antimetabolitici, antitumomi antibiotici, antimitotička sredstva, inhibitori topoizomeraze, citostatici, antiinvazivna sredstva, antiangiogenska sredstva, funkcionalni inhibitori faktora rasta, inhibitori virusne replikacije, inhibitori virusnih enzima, sredstva protiv raka, a-interferoni, B-interferoni, ribavirin, i modulatori TLR-receptora.
In one aspect of the present invention, there is provided a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein represents a hydrogen or fluorine atom or a trifluoromethyl group; 
Spoj s formulom (I), ili njegova farmaceutski prihvatljiva sol, pri čemu R' predstavlja vodikov ili fluorov atom ili skupinu trifluorometil; R* predstavlja skupinu -X-Y-R*;